[Comment requested by the editorial staff].
Haas
S
S
Institut für Experimentelle Onkologie und Therapieforschung, Klinikum rechts der Isar, Munich.
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D004342:Drug Hypersensitivity; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D010976:Platelet Count; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D013923:Thromboembolism / Q000175:diagnosis / Q000188:drug therapy; D013924:Thrombophlebitis / Q000175:diagnosis / Q000188:drug therapy; D013927:Thrombosis / Q000175:diagnosis
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin